Dr. Levin Thomas is a researcher and academician with over twelve years of experience in translational research, pharmacogenomics, and clinical pharmacy. His research has been deeply driven by a passion for understanding how genetic variability influences drug response and improving personalized medicine strategies. He received his PhD in pharmacogenomics from the Manipal Academy of Higher Education (MAHE), Manipal, India, where his doctoral research integrated pharmacogenomics and population pharmacokinetics to optimize isoniazid therapy in tuberculosis patients. His research investigations have generated key evidence supporting NAT2 genotyping as a predictive biomarker for susceptibility to antitubercular drug-induced liver injury and as a covariate for the isoniazid population pharmacokinetic model for precision dosing of isoniazid. Currently, he is a postdoctoral researcher in the Personalized Medicine and Mental Health Unit, University Institute for Biosanitary Research of Extremadura (INUBE), Badajoz, Spain. His major areas of expertise include pharmacogenomic screening of drug metabolizing enzymes and drug transporters, pharmacokinetic analysis, systematic and narrative evidence synthesis, adverse drug reaction surveillance, and the identification and assessment of clinically relevant drug–drug interactions.